Erectile Dysfunction – Pipeline Review, H1 2012

Published : February 2012
No. of Pages : 106

Price:

Erectile Dysfunction – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Erectile Dysfunction - Pipeline Review, H1 2012', provides an overview of the Erectile Dysfunction therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. 'Erectile Dysfunction - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Erectile Dysfunction.
- A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Erectile Dysfunction pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Erectile Dysfunction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Erectile Dysfunction Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Erectile Dysfunction 10
Erectile Dysfunction Therapeutics under Development by Companies 12
Erectile Dysfunction Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Erectile Dysfunction Therapeutics – Products under Development by Companies 21
Erectile Dysfunction Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Erectile Dysfunction Therapeutics Development 23
Eli Lilly and Company 23
Vectura Group plc 24
Chong Kun Dang Pharmaceutical 25
Dong-A Pharmaceutical Co., Ltd. 26
VIVUS, Inc. 27
Warner Chilcott Limited 28
Bayer AG 29
IntelGenx Technologies Corp. 30
NexMed, Inc. 31
NovaDel Pharma, Inc. 32
Palatin Technologies, Inc. 33
Yuhan Corporation 34
Plethora Solutions Holdings plc 35
Rexahn Pharmaceuticals, Inc. 36
Global Health Ventures Inc. 37
Quatrx Pharmaceutical Company 38
Medisyn Technologies, Inc. 39
Ion Channel Innovations, LLC 40
Erectile Dysfunction – Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
Avanafil - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Vitaros - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Bremelanotide - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
X-Excite - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Zoraxel - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
VR004 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Duromist - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Invicorp - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Viagra - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Alfuzosin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Bone Marrow Mononucleated Cells - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Zydena - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Zydena - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Viagra - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BAY60-4552 + Vardenafil - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Testim + Viagra - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
LY900010 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Fispemifene - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Avanafil - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
INT007 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Dehydroepiandrosterone - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Testosterone - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Folic Acid + Tadalafil - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pVAX-hSlo - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Simvastatin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
WC3043 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Avanafil + Enalapril - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Avanafil + Amlodipine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PDE5 Inhibition - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
YHD1023 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Erectile Dysfunction Therapeutics – Drug Profile Updates 87
Erectile Dysfunction Therapeutics – Discontinued Products 96
Erectile Dysfunction Therapeutics - Dormant Products 97
Erectile Dysfunction – Product Development Milestones 98
Featured News & Press Releases 98
Jan 17, 2012: VIVUS Announces REVIVE Trial Results For Avanafil Published In JSM That Demonstrates Significant Improvement In Erectile Function 98
Jan 17, 2012: Apricus Bio Announces Allowance Of Israeli Patent For Vitaros For Topical Treatment Of Premature Ejaculation 99
Jan 17, 2012: Ampio's Zertane Combinations To Receive Two New European Patents For Treatment Of Male Sexual Dysfunctions 100
Jan 10, 2012: Kedem Pharmaceuticals Completes North American Dosage Forms For X-Excite 100
Dec 15, 2011: Apricus Bio Announces Oral Presentation Of Efficacy And Clinical Safety Data For Vitaros At African Society For Sexual Medicine Conference 101
Dec 05, 2011: Vivus Announces Presentation Of Avanafil Data At European Society Of Sexual Medicine Meeting 101
Nov 30, 2011: Apricus Bio Announces Podium Presentation Of Efficacy And Clinical Safety Data For Vitaros At European Sexual Society Medicine Conference 102
Nov 14, 2011: VIVUS Presents New Analyses From Phase III Study Of Avanafil At Annual Meeting Of Sexual Medicine Society of North America 103
Nov 10, 2011: VIVUS To Present Data On Avanafil At Sexual Medicine Society Of North America Meeting 103
Oct 25, 2011: Pfizer Selects Adams & Knight To Solidify VIAGRA Brand In Africa And Middle East Markets 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 106
Contact Us 106
Disclaimer 106

List of Tables
Number of Products Under Development for Erectile Dysfunction, H1 2012 10
Products under Development for Erectile Dysfunction – Comparative Analysis, H1 2012 11
Number of Products under Development by Companies, H1 2012 13
Number of Products under Development by Companies, H1 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2012 16
Comparative Analysis by Late Stage Development, H1 2012 17
Comparative Analysis by Mid Clinical Stage Development, H1 2012 18
Comparative Analysis by Early Clinical Stage Development, H1 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 20
Products under Development by Companies, H1 2012 21
Products under Investigation by Universities/Institutes, H1 2012 22
Eli Lilly and Company, H1 2012 23
Vectura Group plc, H1 2012 24
Chong Kun Dang Pharmaceutical, H1 2012 25
Dong-A Pharmaceutical Co., Ltd., H1 2012 26
VIVUS, Inc., H1 2012 27
Warner Chilcott Limited, H1 2012 28
Bayer AG, H1 2012 29
IntelGenx Technologies Corp., H1 2012 30
NexMed, Inc., H1 2012 31
NovaDel Pharma, Inc., H1 2012 32
Palatin Technologies, Inc., H1 2012 33
Yuhan Corporation, H1 2012 34
Plethora Solutions Holdings plc, H1 2012 35
Rexahn Pharmaceuticals, Inc., H1 2012 36
Global Health Ventures Inc., H1 2012 37
Quatrx Pharmaceutical Company, H1 2012 38
Medisyn Technologies, Inc., H1 2012 39
Ion Channel Innovations, LLC, H1 2012 40
Assessment by Monotherapy Products, H1 2012 41
Assessment by Combination Products, H1 2012 42
Assessment by Stage and Route of Administration, H1 2012 44
Assessment by Stage and Molecule Type, H1 2012 46
Erectile Dysfunction Therapeutics – Drug Profile Updates 87
Erectile Dysfunction Therapeutics – Discontinued Products 96
Erectile Dysfunction Therapeutics – Dormant Products 97

List of Figures
Number of Products under Development for Erectile Dysfunction, H1 2012 10
Products under Development for Erectile Dysfunction – Comparative Analysis, H1 2012 11
Products under Development by Companies, H1 2012 12
Products under Investigation by Universities/Institutes, H1 2012 15
Late Stage Products, H1 2012 17
Mid Clinical Stage Products, H1 2012 18
Early Clinical Stage Products, H1 2012 19
Discovery and Pre-Clinical Stage Products, H1 2012 20
Assessment by Monotherapy Products, H1 2012 41
Assessment by Combination Products, H1 2012 42
Assessment by Route of Administration, H1 2012 43
Assessment by Stage and Route of Administration, H1 2012 44
Assessment by Molecule Type, H1 2012 45
Assessment by Stage and Molecule Type, H1 2012 46

Erectile Dysfunction – Pipeline Review, H1 2012

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: